These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.
    Author: Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Nishikage T, Nagai K, Kawano T.
    Journal: Hepatogastroenterology; 2008; 55(86-87):1631-5. PubMed ID: 19102357.
    Abstract:
    BACKGROUND/AIMS: This study documents the clinical efficacy and toxicity of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer. METHODOLOGY: From February 2002 to February 2007, 20 patients with metastatic or locally recurrent or residual disease previously treated with cisplatin-based chemotherapy or chemoradiotherapy were included. The median age was 66.0 (range 52-74) years, and 17 patients had undergone a previous esophagectomy. A total of 36 cycles with docetaxel 60 mg/m2 plus nedaplatin 80 mg/m2 were administered. RESULTS: The response rate was 25% including one complete response, and the rate of disease stabilization (% of complete response, partial response and stable disease) was 80%. The median progression-free survival was 14 weeks and the median overall survival was 26 weeks. Severe neutropenia occurred in 12 patients (grade 3/4 = 4/8) and 5 out of 20 patients showed severe febrile neutropenia (grade 3/4 = 4/1), whereas no severe non-hematological toxicity was observed. CONCLUSIONS: In conclusion, the combination chemotherapy of docetaxel and nedaplatin did not show drastic clinical efficacy. However, it was considered to be a feasible regimen as tumor dormancy therapy in CDDP-pretreated esophageal cancer, and to have a potent possibility to become a useful second-line chemotherapy for relapsed or refractory esophageal cancer. The control and prevention of severe neutropenia and febrile neutropenia is also very important in use of this regimen.
    [Abstract] [Full Text] [Related] [New Search]